Cargando…
Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or ‐resistant myeloma cells
Mechanisms underlying interactions between a novel, clinically relevant circularized tumor necrosis factor‐related apoptosis inducing ligand (TRAIL) agonist, circularly permuted TRAIL (CPT) have been examined in multiple myeloma (MM) cells sensitive or resistant to bortezomib (BTZ). Various MM cell...
Autores principales: | Leng, Yun, Hu, Xiaoyan, Li, Lin, Nkwocha, Jewel, Satta, Toshihisa, Sharma, Kanika, Kmeiciak, Maciej, Zhou, Huixing, Zhang, Zhiyao, Zhou, Liang, Chen, Wenming, Grant, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084357/ https://www.ncbi.nlm.nih.gov/pubmed/35789025 http://dx.doi.org/10.1002/hon.3045 |
Ejemplares similares
-
Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study
por: Wang, Huijuan, et al.
Publicado: (2020) -
The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2019) -
SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
por: Zhou, Pan, et al.
Publicado: (2022) -
Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009) -
ABT-737 synergizes with Bortezomib to kill melanoma cells
por: Reuland, Steven N., et al.
Publicado: (2011)